Kufor-Rakeb Syndrome (PARK9)

Kufor-Rakeb Syndrome (PARK9)

Introduction

Kufor Rakeb Syndrome (Park9) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Kufor-Rakeb Syndrome (PARK9)

Introduction

Kufor Rakeb Syndrome (Park9) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<table class="infobox infobox-disease"> [@kuforrakeba]
<tr> [@phenotypic]
<th class="infobox-header" colspan="2">Kufor-Rakeb Syndrome (PARK9)</th> [@cmyc]
</tr> [@quantitative]
<tr> [^6]
<td class="infobox-image" colspan="2"> [^7]
<em>Brain MRI showing generalized atrophy and basal ganglia iron deposition</em> [^8]
</td> [^9]
</tr> [^10]
<tr> [^11]
<td class="label">Also Known As</td> [^12]
<td>Parkinson Disease 9 (PARK9), Pallido-Pyramidal Syndrome, Juvenile-Onset Parkinsonism with Brain Iron Accumulation</td>
</tr>
<tr>
<td class="label">ICD-10</td>
<td>G20.A (Parkinson disease due to genetic cause)</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://www.omim.org/entry/606693" target="_blank">606693</a></td>
</tr>
<tr>
<td class="label">Inheritance</td>
<td>Autosomal recessive</td>
</tr>
<tr>
<td class="label">Gene</td>
<td><a href="/entities/atp13a2"><em>ATP13A2</em></a>, chromosome 1p36.13</td>
</tr>
<tr>
<td class="label">Protein</td>
<td>ATP13A2 / PARK9 (lysosomal P5B-type ATPase)</td>
</tr>
<tr>
<td class="label">Onset</td>
<td>Juvenile (typically 11–16 years)</td>
</tr>
<tr>
<td class="label">Key Features</td>
<td>Levodopa-responsive parkinsonism, supranuclear gaze palsy, pyramidal signs, dementia, brain iron accumulation</td>
</tr>
<tr>
<td class="label">Prevalence</td>
<td>Ultra-rare; fewer than 100 families reported worldwide</td>
</tr>
</table>

Overview

Kufor-Rakeb syndrome (KRS), designated PARK9, is an ultra-rare autosomal recessive neurodegenerative disorder representing one of the most aggressive forms of genetic parkinsonism. The disease is caused by biallelic loss-of-function mutations in the ATP13A2 gene, which encodes a lysosomal P5B-type ATPase involved in polyamine transport, metal homeostasis, and lysosomal function.
[@kuforrakeb]

KRS was first described in 2001 by Najim al-Din et al. in a consanguineous Jordanian family from the village of Kufor-Rakeb, near Irbid. The affected individuals presented with juvenile-onset parkinsonism, pyramidal tract dysfunction, supranuclear gaze palsy, and dementia — a combination that distinguished this syndrome from other juvenile parkinsonism forms. The causative gene was mapped in 2001 and identified as ATP13A2 in 2006 by Ramirez et al.
[@kuforrakeba]

KRS occupies a unique position at the intersection of Mendelian parkinsonism, [neurodegeneration with brain iron accumulation (NBIA)](/diseases/neurodegeneration-brain-iron-accumulation), and [lysosomal storage disorders](/diseases/lysosomal-storage-disorders). Brain MRI often reveals iron deposition in the putamen and caudate nucleus alongside generalized cerebral atrophy, linking KRS pathogenetically to the NBIA spectrum. The disease typically manifests in adolescence and progresses rapidly, with patients often dying by the third decade of life.
[@phenotypic]

Epidemiology

Kufor-Rakeb syndrome is one of the rarest forms of genetic parkinsonism, with fewer than 100 families reported worldwide since its initial description. Cases have been identified across diverse ethnic groups, including families of Jordanian, Chilean, Pakistani, Afghan, Japanese, Italian, Brazilian, and European descent. The true prevalence is unknown but likely underestimated due to diagnostic challenges and overlap with other juvenile parkinsonism forms.
[@cmyc]

The disease shows no sex predilection. Onset typically occurs in the second decade of life, with a median age of onset around 12–16 years. Consanguineous families are overrepresented due to the autosomal recessive inheritance pattern.
[@kuforrakeba]

Genetics and Molecular Pathogenesis

ATP13A2 Gene and Protein

ATP13A2 is located on chromosome 1p36.13 and encodes a 1180-amino acid transmembrane protein with 10 transmembrane domains. ATP13A2 belongs to the P5B subgroup of P-type ATPases and is primarily localized to the lysosomal and late endosomal membrane, with additional expression at the endoplasmic reticulum.[@quantitative]

Over 30 pathogenic mutations have been identified, including missense, nonsense, splice-site, and frameshift variants. Most mutations result in misfolded protein that is retained in the ER and degraded by the proteasome, leading to effective loss of function at the lysosomal membrane.
[^6]

Polyamine Transport

The primary biochemical function of ATP13A2 is the ATP-dependent transport of polyamines — spermine and spermidine — from the lysosomal lumen to the cytosol. Structural studies have revealed the conformational cycle of ATP13A2 during polyamine transport, showing how it couples ATP hydrolysis to substrate translocation across the lysosomal membrane.
[^7]

Loss of ATP13A2 function leads to:

• Lysosomal polyamine accumulation: Toxic concentrations of polyamines within lysosomes impair lysosomal acidification and degradative capacity
• Cytosolic polyamine depletion: Reduced cytosolic spermine/spermidine levels compromise mitochondrial protection, as polyamines normally serve as [reactive oxygen species (ROS)](/entities/ros) scavengers
• Impaired β-glucocerebrosidase (GCase) activity: Accumulated lysosomal polyamines alter GCase-lipid interactions through electrostatic mechanisms, linking KRS pathogenesis to [GBA](/entities/gba)-associated Parkinson's Disease

Metal Homeostasis

ATP13A2 plays important roles in intracellular metal homeostasis:

• Zinc dyshomeostasis: Loss of ATP13A2 disrupts lysosomal zinc sequestration, leading to cytosolic zinc accumulation that impairs lysosomal function and promotes [α-synuclein](/proteins/alpha-synuclein) aggregation. PARK9-deficient cells show increased expression of zinc transporters as a compensatory response.

• Manganese toxicity: ATP13A2 contributes to cellular manganese detoxification, and its deficiency sensitizes [neurons](/entities/neurons) to manganese-induced oxidative damage
• Iron accumulation: Though the mechanism is indirect, ATP13A2 deficiency leads to brain iron deposition, possibly through impaired endolysosomal iron trafficking[@quantitative]

Downstream Pathological Cascades

ATP13A2 deficiency triggers multiple interconnected neurodegenerative cascades:

Clinical Features

Core Motor Features

The motor presentation of KRS combines features of both parkinsonism and pyramidal tract dysfunction:

• Levodopa-responsive parkinsonism: Prominent bradykinesia, rigidity, mask-like facies, and postural instability; initial response to [levodopa](/therapeutics/levodopa) is typically good but complicated by early motor fluctuations and dyskinesias
• Facial-faucial-finger polymyoclonus: Involuntary myoclonic jerks of the face, palate, and hands — a characteristic feature that helps distinguish KRS from other juvenile parkinsonism forms
• Pyramidal tract signs: Spasticity, hyperreflexia, extensor plantar responses, and paraparesis
• Dystonia: May be generalized or focal, sometimes preceding parkinsonism
• Supranuclear gaze palsy: Impaired vertical and horizontal gaze, with preserved reflexive eye movements — a hallmark feature resembling [progressive supranuclear palsy](/diseases/progressive-supranuclear-palsy)[@phenotypic]

Cognitive and Psychiatric Features

Cognitive decline is a prominent and progressive feature:

• Dementia: Progressive cognitive impairment, typically subcortical in pattern, with impaired executive function, processing speed, and visuospatial abilities
• Behavioral changes: Aggression, impulsivity, and personality changes
• Psychosis: Visual hallucinations and paranoid ideation occur in a subset of patients, sometimes as presenting symptoms; recent reports have documented antipsychotic-responsive psychosis in KRS

Additional Features

• Oculogyric crises: Sustained involuntary conjugate upward deviation of the eyes
• Facial dyskinesia: Involuntary facial movements
• Olfactory dysfunction: Reduced sense of smell, similar to idiopathic [Parkinson's disease](/diseases/parkinsons-disease)
• Autonomic dysfunction: Bladder urgency, constipation
• Minipolymyoclonus: Fine, rapid involuntary movements of the fingers when outstretched[@cmyc]

Diagnosis

Clinical Criteria

Diagnosis should be suspected in patients presenting with:

The combination of juvenile parkinsonism with supranuclear gaze palsy and pyramidal signs is highly suggestive of KRS.[@phenotypic]

Neuroimaging

Brain MRI reveals:

• Generalized cerebral and cerebellar atrophy: Progressive, often symmetric
• Putaminal and caudate iron deposition: Visible as hypointensity on T2*-weighted and susceptibility-weighted imaging (SWI), linking KRS to the [NBIA](/diseases/nbia) spectrum
• Diffuse cortical thinning: Progressive gray matter loss
• DaTSCAN: Reduced dopamine transporter binding in the striatum, confirming nigrostriatal degeneration

Genetic Testing

Definitive diagnosis requires identification of biallelic pathogenic variants in ATP13A2 through targeted gene sequencing or next-generation sequencing panels for genetic parkinsonism or NBIA. Whole-exome sequencing may be necessary for novel or atypical variants.[^6]

Differential Diagnosis

The differential diagnosis of juvenile-onset parkinsonism with additional neurological features includes:

• [Parkin](/proteins/parkin)-related parkinsonism (PARK2): Earlier onset, slower progression, no supranuclear gaze palsy
• [PINK1](/proteins/pink1-protein)-related parkinsonism (PARK6): Slower progression, no pyramidal signs
• [DJ-1](/proteins/dj1-park7)-related parkinsonism (PARK7): Very rare, no brain iron accumulation
• [NBIA](/diseases/nbia) subtypes: [PKAN](/diseases/pkan), BPAN, MPAN — distinguished by specific gene testing and neuroimaging patterns
• [progressive supranuclear palsy](/diseases/progressive-supranuclear-palsy): Later onset, different [tau](/proteins/tau)-based pathology
• [Wilson's Disease](/diseases/wilson-disease): Copper metabolism disorder — distinguished by ceruloplasmin, copper studies, Kayser-Fleischer rings
• [Huntington's disease](/mechanisms/huntington-pathway): Juvenile Huntington's (Westphal variant) may present similarly — distinguished by [HTT](/proteins/htt-protein) gene testing[@phenotypic]

Treatment and Management

Symptomatic Treatment

• Levodopa: The mainstay of motor symptom management; most patients show initial good response but develop [levodopa](/therapeutics/levodopa)-induced dyskinesias relatively early, often within 1–2 years of treatment initiation
• Dopamine agonists: May be tried, though benefit is variable
• Antipsychotics: For psychotic symptoms; atypical antipsychotics (quetiapine, clonazepam) preferred to minimize extrapyramidal side effects. Recent reports document favorable response to clozapine in KRS-associated psychosis

• Antispasticity agents: Baclofen, tizanidine for pyramidal spasticity
• Physical and occupational therapy: Essential for maintaining mobility and function
• Speech therapy: For dysarthria and dysphagia
• Nutritional support: As disease progresses[@cmyc]

Emerging Research Directions

• Gene therapy: AAV-mediated ATP13A2 gene replacement in animal models is being explored as a potential curative approach
• Polyamine supplementation: Exogenous spermidine administration may compensate for impaired lysosomal polyamine export, with preclinical studies showing neuroprotective effects
• Iron chelation: Given the iron accumulation phenotype, deferiprone and other iron chelation strategies are under investigation
• Substrate reduction therapy: Targeting polyamine or lipid accumulation pathways
• Zinc modulators: Compounds that restore zinc homeostasis may mitigate downstream effects of ATP13A2 deficiency[^10]

Prognosis

KRS is among the most aggressive forms of genetic parkinsonism. Disease onset typically occurs in early adolescence (ages 11–16), and the condition progresses rapidly with accumulating motor disability, cognitive decline, and loss of independence. Without effective disease-modifying therapy, patients often die in their late 20s to 30s due to complications including aspiration pneumonia, immobility-related complications, and status epilepticus. The rapidly progressive nature of KRS underscores the critical importance of ATP13A2 function for neuronal survival and highlights the urgent need for targeted therapies.
[@phenotypic]

Animal Models

ATP13A2 knockout models have been developed in multiple species:

• Mouse models: Atp13a2-knockout mice develop progressive motor deficits, lipofuscinosis, and α-synuclein accumulation, recapitulating key features of the human disease
• Rat models: A 2025 phenotypic characterization of Atp13a2-knockout rats demonstrated progressive parkinsonism-like features including motor impairment, dopaminergic neurodegeneration, and lysosomal dysfunction, providing a valuable preclinical model for therapeutic testing

• Drosophila and C. elegans: Invertebrate models have been valuable for high-throughput drug screening and mechanistic studies

External Links

• [OMIM: Kufor-Rakeb Syndrome](https://www.omim.org/entry/606693)
• [NORD: Kufor-Rakeb Syndrome](https://rarediseases.org/rare-/diseases/kufor-rakeb-syndrome/)
• [GeneReviews: ATP13A2-Related Disorder](https://www.ncbi.nlm.nih.gov/books/NBK1421/)
• [MalaCards: Kufor-Rakeb Syndrome](https://www.malacards.org/card/kufor_rakeb_syndrome)

See Also

• [α-synuclein](/proteins/alpha-synuclein)
• [astrocyte](/cell-types/astrocytes)
• [Parkin](/proteins/parkin)
• [PINK1](/proteins/pink1-protein)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Tau Pathology](/mechanisms/tau-pathology)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [ALS](/diseases/amyotrophic-lateral-sclerosis)
• [Huntington's Disease](/mechanisms/huntington-pathway)
• [neuroinflammation](/mechanisms/neuroinflammation)

Background

The study of Kufor Rakeb Syndrome (Park9) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Recent Research (2024-2026)

This section highlights recent publications relevant to this disease.

• [Kufor-Rakeb syndrome: a cohort-based clinical, imaging and genetic profile.](https://pubmed.ncbi.nlm.nih.gov/41493629/) (2026 Jan 6) - Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
• [Kufor-Rakeb Syndrome in a Guatemalan Patient With an ATP13A2 Gene Pathogenic Variant: A Case Report.](https://pubmed.ncbi.nlm.nih.gov/41306646/) (2025) - Case reports in genetics
• [Phenotypic characterization of an Atp13a2 knockout rat model of Parkinson's disease.](https://pubmed.ncbi.nlm.nih.gov/41253848/) (2025 Nov 18) - NPJ Parkinson's disease
• [C-Myc Indirectly Controls ATP13A2 Levels via HIF-1α Activation.](https://pubmed.ncbi.nlm.nih.gov/41292106/) (2025 Nov) - Journal of neurochemistry
• [Quantitative Iron Measurements in the Basal Ganglia of NBIA Patients Using QSM: Insights From a Tertiary Center.](https://pubmed.ncbi.nlm.nih.gov/40817817/) (2025 Nov) - Annals of clinical and translational neurology

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
• [BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/) - Developmental gene expression data

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
• [BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/) - Developmental gene expression data

References